Hospital Universitari de Bellvitge -ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2018

  1. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

    Clinical and Translational Oncology, Vol. 20, Núm. 4, pp. 443-447

2015

  1. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis

    Oncologist, Vol. 20, Núm. 2, pp. 111-112